Skip to main content
Fig. 1 | Diagnostic and Prognostic Research

Fig. 1

From: Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study

Fig. 1

Study overview. Participants will be recruited to cohorts based on criteria detailed in Table 1. ARLD, alcohol-related fatty liver disease; ALP, alkaline phosphatase; ALT, alanine transaminase; K18, cytokeratin-18; DILI, drug-induced liver injury; GLDH, glutamate dehydrogenase; HMGB1, high mobility group box 1; MCSF1R, macrophage colony-stimulating factor 1 receptor; NAFLD, non-alcoholic fatty liver disease; TBL, total bilirubin; ULN, upper limit of normal

Back to article page

Diagnostic and Prognostic Research

ISSN: 2397-7523

Contact us